

August 7, 2025



# Cellecstar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 14, 2025

FLORHAM PARK, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Cellecstar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that the Company will report financial results for the second quarter ended June 30, 2025, and provide a corporate update on August 14, 2025, at 8:30 a.m. Eastern Time.

#### Conference Call & Webcast Details:

Date: Thursday, August 14, 2025  
Time: 8:30 am Eastern Time  
Toll Free: 1-800-717-1738  
Conference ID: 94699  
Webcast: [Click HERE](#)

A replay of the corporate presentation will be available on the [Events](#) section of the Company's [Investor Relations](#) website.

#### About Cellecstar Biosciences, Inc.

Cellecstar Biosciences is a late-stage clinical biopharmaceutical company focused on the discovery and development of proprietary drugs for the treatment of cancer, independently and through research and development collaborations. The company's core objective is to leverage its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform to develop the next-generation of cancer cell-targeting treatments, delivering improved efficacy and better safety as a result of fewer off-target effects.

The company's product pipeline includes: iopofosine I 131, a PDC designed to provide targeted delivery of iodine-131 (radioisotope), for which the FDA has granted Breakthrough Therapy Designation; CLR 121225, an actinium-225 based program being targeted to several solid tumors with significant unmet need, such as pancreatic cancer; and CLR 121125, an iodine-125 Auger-emitting program targeted in other solid tumors, such as triple negative breast, lung and colorectal, as well as proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets.

In addition, iopofosine I 131 has been studied in Phase 2b trials for relapsed or refractory multiple myeloma (MM) and central nervous system (CNS) lymphoma, and the CLOVER-2 Phase 1b study, targeting pediatric patients with high-grade gliomas, for which Cellecstar is eligible to receive a Pediatric Review Voucher from the FDA upon approval. The FDA has also granted iopofosine I 131 six Orphan Drug, four Rare Pediatric Drug and two Fast Track

Designations for various cancer indications.

For more information, please visit [www.cellectar.com](http://www.cellectar.com) or join the conversation by liking and following us on the company's social media channels: [X](#), [LinkedIn](#), and [Facebook](#).

**Investor Contact:**

Anne Marie Fields

Precision AQ

212-362-1200

[annemarie.fields@precisionaq.com](mailto:annemarie.fields@precisionaq.com)



Source: Cellectar Biosciences, Inc.